1. Home
  2. FTHM vs ACXP Comparison

FTHM vs ACXP Comparison

Compare FTHM & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fathom Holdings Inc.

FTHM

Fathom Holdings Inc.

HOLD

Current Price

$0.66

Market Cap

28.8M

Sector

Finance

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.44

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTHM
ACXP
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
6.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
FTHM
ACXP
Price
$0.66
$1.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$2.50
$95.50
AVG Volume (30 Days)
89.1K
179.1K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
32.71
N/A
EPS
N/A
N/A
Revenue
$420,477,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.45
N/A
52 Week Low
$0.40
$1.31
52 Week High
$3.37
$8.34

Technical Indicators

Market Signals
Indicator
FTHM
ACXP
Relative Strength Index (RSI) 39.88 47.60
Support Level $0.48 $1.33
Resistance Level $0.71 $1.75
Average True Range (ATR) 0.04 0.06
MACD 0.00 0.00
Stochastic Oscillator 42.48 37.50

Price Performance

Historical Comparison
FTHM
ACXP

About FTHM Fathom Holdings Inc.

Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: